Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495911 | 0.83 | RXFP1 (0.38) | CYP2C9ESR1ESR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL584413 | 0.82 | RXFP1 (0.38) | CYP2C9ESR1ESR2MEN1KMT2A | |
| SCHEMBL381409 | 0.80 | CYP2C9 (0.48) | NPC1LMNACYP2C9KDM4EESR1 | |
| SCHEMBL2227779 | 0.80 | CYP2C9 (0.47) | NPC1LMNACYP2C9KDM4EESR1 | |
| SCHEMBL7578109 | 0.75 | ESR1 (0.37) | CYP2C9ESR1ESR2MEN1MAPK1 | |
| SCHEMBL5468852 | 0.73 | MEN1 (0.53) | NPC1LMNAKDM4EESR1ESR2 | |
| SCHEMBL21635716 | 0.70 | ALDH1A1 (0.38) | NPC1LMNACYP2C9KDM4EESR1 | |
| SCHEMBL7759506 | 0.69 | ALDH1A1 (0.39) | NPC1LMNACYP2C9KDM4EESR1 | |
| SCHEMBL24111837 | 0.67 | HSP90AA1 (0.36) | CYP2C9ESR1ESR2MEN1KMT2A | |
| Fluorescin SCHEMBL31164673 | 0.66 | CYP2C9 (0.71) | CYP2C9ESR1ESR2MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135275-B2 | Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets | NOVO NORDISK HEALTHCARE AG (CH) | 2021-10-05 | — | — | US | disclosed |
| EP-2680875-B1 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS | NOVO NORDISK HEALTHCARE AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-20190083587-A1 | Coagulation factor-targeting to TLT-1 on activated platelets | NOVO NORDISK AS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-20160263230-A1 | Coagulation Factor-Targeting to TLT-1 on Activated Platelets | NOVO NORDISK HEALTHCARE AG (CH) | 2016-09-15 | — | — | US | disclosed |
| US-20160251409-A1 | Targeted Delivery of Factor VIII Proteins to Platelets | NOVO NORDISK AS (DK) | 2016-09-01 | — | — | US | disclosed |
| EP-2680875-A1 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS | Novo Nordisk A/S (DK) | 2014-01-08 | — | — | EP | disclosed |
| US-20130337537-A1 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS | NOVO NORDISK A/S (DK) | 2013-12-19 | — | — | US | disclosed |
| EP-2417155-B1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK AS (DK) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012117091-A1 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS | NOVO NORDISK A/S (DK) | 2012-09-07 | — | — | WO | disclosed |
| US-20120093840-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2012-04-19 | — | — | US | disclosed |
| EP-2417155-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | Novo Nordisk A/S (DK) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115866-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083587-A1 | Coagulation factor-targeting to TLT-1 on activated platelets | TFPI, F13B, F3 | NPC1 3024/4885LMNA 1793/4885CYP2C9 4666/4885 |
| US-20120093840-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | F13B, F8, F13A1 | NPC1 3486/4885LMNA 1345/4885CYP2C9 4508/4885 |
| US-20160251409-A1 | Targeted Delivery of Factor VIII Proteins to Platelets | F13B, F8, F13A1 | NPC1 3486/4885LMNA 1345/4885CYP2C9 4508/4885 |
| US-11135275-B2 | Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets | TFPI, F3, F11 | NPC1 2901/4885LMNA 1879/4885CYP2C9 4066/4885 |
| US-20160263230-A1 | Coagulation Factor-Targeting to TLT-1 on Activated Platelets | TFPI, F13B, F3 | NPC1 3024/4885LMNA 1793/4885CYP2C9 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.